Is GeNeuro S.A. (GNRO.PA) a Buy, Sell, or Hold?
PAR : GNRO.PA
GeNeuro S.A.
$0.0308 EUR
$0 (0.0%)
- Volume
- 67.78K
- Average Volume
- 154.31K
- Market Capitalization
- $911.56K
- P/E Ratio
- -0.05
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.15
- Year Low
- $0.02
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.37
Company Overview
PAR
Jesus Martin-Garcia
Biotechnology
Healthcare
GNRO.PA
17
CH
EUR
Liquidity Metrics
-0.97
0.37
0.37
0.29
0.00
Sales & Valuation
-$
0.00
-0.06
-0.09
-0.41
Profitability
-$0.59
-$14.76M
0.00%
0.00%
239.67%
-231.96%
P/E Metrics
-0.05
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-27.56
1/9
-$3.92M
$6.36M
$20.14M
-$27.6M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Alois Lang | Chief Development Officer |
| Anke Post | Chief Medical Officer |
| Hervé Perron | Chief Scientific Officer |
| Jesus Martin-Garcia | Chairman & Chief Executive Officer |
| Miguel Payró | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About GeNeuro S.A. (PAR:GNRO.PA) Stock
GeNeuro S.A. is a clinical-stage biopharmaceutical entity focused on developing therapies for various neurodegenerative and autoimmune disorders. Its leading therapeutic asset, temelimab, a monoclonal antibody, has successfully completed Phase IIb clinical trials for multiple sclerosis. Furthermore, temelimab is currently in Phase IIa for treating type 1 diabetes and in Phase I development for chronic inflammatory demyelinating polyneuropathy (CIDP). The company is actively involved in multiple collaborative research and development initiatives, including an alliance with The National Institute of Neurological Disorders and Stroke (NINDS) to engineer novel therapeutic antibodies for amyotrophic lateral sclerosis (ALS), and partnerships with academic laboratories exploring treatments for in ... flammatory psychosis. GeNeuro also maintains research collaborations with the International Center for Infectiology Research (ICIR) and Northwestern University, specifically investigating the human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. Founded in 2006, the company is headquartered in Plan-les-Ouates, Switzerland.
Frequently Asked Questions
-
What is the current GeNeuro S.A. (GNRO.PA) stock price?
-
GeNeuro S.A.(PAR:GNRO.PA) stock price is $0.0308 in the last trading session. During the trading session, GNRO.PA stock reached the peak price of $0.1485 while $0.0198 was the lowest point it dropped to. The percentage change in GNRO.PA stock occurred in the recent session was 0.0% while the dollar amount for the price change in GNRO.PA stock was $0.
-
GNRO.PA's industry and sector of operation?
-
The PAR listed GNRO.PA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GNRO.PA?
-
Alois Lang | Chief Development Officer
Anke Post | Chief Medical Officer
Hervé Perron | Chief Scientific Officer
Jesus Martin-Garcia | Chairman & Chief Executive Officer
Miguel Payró | Chief Financial Officer -
How many employees does GNRO.PA have?
-
Number of GNRO.PA employees currently stands at 17. GNRO.PA operates from 3 chemin du PrE-Fleuri, Plan-les-Ouates, None 1228, CH.
-
Link for GNRO.PA official website?
-
Official Website of GNRO.PA is: https://www.geneuro.com
-
How do I contact GNRO.PA?
-
GNRO.PA could be contacted at phone #41 22 552 48 00 and can also be accessed through its website. GNRO.PA operates from 3 chemin du PrE-Fleuri, Plan-les-Ouates, None 1228, CH.
-
How many shares of GNRO.PA are traded daily?
-
The average number of GNRO.PA shares traded daily for last 3 months was 154.31K.
-
What is the market cap of GNRO.PA currently?
-
The market value of GNRO.PA currently stands at $911.56K with its latest stock price at $0.0308